<DOC>
	<DOCNO>NCT02355184</DOCNO>
	<brief_summary>This study Phase 2b , multi-center , extension study design evaluate long-term efficacy , safety , tolerability PRO 140 monotherapy maintenance viral suppression patient stable combination antiretroviral therapy complete 12 week treatment PRO140_CD01 Treatment Substitution Study without experience virologic failure . Consenting patient continue receive PRO 140 monotherapy 160 additional week . Total treatment duration PRO 140 161 week one week overlap exist retroviral regimen PRO 140 end treatment extension phase subject experience virologic failure .</brief_summary>
	<brief_title>An Extension Protocol PRO 140_CD01 TS Study</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>PRO-140 monoclonal antibody</mesh_term>
	<mesh_term>HIV Antibodies</mesh_term>
	<criteria>1 . Subjects complete 12 week treatment PRO 140_CD01 study without experience virologic failure . 2 . Both male female patient partner childbearing potential must agree use appropriate birth control method ( birth control pill , barrier , abstinence ) throughout study duration ( exclude woman childbearing potential men sterilize ) . Females childbearing potential must negative urine pregnancy test prior receive first dose study drug . 3 . Willing able participate aspect study , include use SC medication , completion subjective evaluation , attendance schedule clinic visit , compliance protocol requirement evidence provide write informed consent . 1 . Not currently enrol PRO140_CD01 Treatment Substitution Study 2 . Any acquire immune deficiency syndrome ( AIDS ) define illness accord 1993 Centers Disease Control Prevention ( CDC ) AIDS surveillance definition 3 . Laboratory test value â‰¥ grade 4 DAIDS laboratory abnormality . 4 . Females pregnant , lactating , breastfeeding , plan become pregnant study 5 . Unexplained temperature &gt; 38.5C ( 101.3F ) seven consecutive day within 14 day prior first study dose 6 . Diagnosed either substance dependence substance abuse history concomitant condition ( e.g. , medical , psychologic , psychiatric ) opinion primary care provider and/or site investigator would interfere subject 's successful completion study requirement 7 . Any clinical condition , Investigator 's judgment , would potentially compromise study compliance ability evaluate safety/efficacy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>